ASPIRE Product Use Management: HIV Infection



Protocol Reference: Section 9.3 and 9.6

ASPIRE Product Use Management: Allergic Reaction to the Vaginal Ring

Protocol Reference: Section 9.3

ASPIRE Product Use Management: Pregnant



*** Only resume if not breastfeeding. After a pregnancy hold, VR use should not be resumed earlier than 2 weeks after a 1st trimester loss, or earlier than 4 weeks after 2nd trimester (or later) pregnancy loss or delivery. Product restart timelines should begin when the pregnancy is lost (i.e., bleeding, elective termination, etc). This restart timeline should only be based off a negative pregnancy test if the date of pregnancy loss is completely unknown.**

Protocol Reference: Sections 9.3 and 9.7

ASPIRE Product Use Management: Breastfeeding

Protocol Reference: Section 9.3

ASPIRE Product Use Management: PEP



Protocol Reference: Section 9.3

ASPIRE Product Use Management: Grade 1 and Grade 2 Adverse Events



Protocol Reference: Section 9.4

ASPIRE Product Use Management: Grade 3 Adverse Events



Protocol Reference: Section 9.4

ASPIRE Product Use Management: Grade 4 Adverse Events



***Temporary product hold must continue until a recommendation is received from the PSRT.**

Protocol Reference: Section 9.4

ASPIRE Product Use Management: Sexually Transmitted Infections and Reproductive Tract Infections



***Treat per local guidelines, using observed single dose regimens whenever possible.**

Protocol Reference: Section 9.5

ASPIRE Product Use Management: Superficial epithelial disruption (abrasion/ peeling)



Protocol Reference: Section 9.5

ASPIRE Product Use Management: Deep epithelial disruption (ulceration)



Protocol Reference: Section 9.4

ASPIRE Product Use Management: Localized erythema or edema (area < 50% of vulvar surface or combined vaginal and cervical surface)



Protocol Reference: Section 9.4

ASPIRE Product Use Management: Generalized erythema or severe edema (area > 50% of vulvar surface or combined vaginal and cervical surface affected by erythema)



Protocol Reference: Section 9.4

ASPIRE Product Use Management: Unexpected genital bleeding



***If determined to be due to deep epithelial disruption, refer to those guidelines; otherwise continue study product use**

***VR may be held in presence of Grade 3 related or Grade 4 unexpected genital bleeding per clinician discretion (protocol section 9.4)**

Protocol Reference: Section 9.5

ASPIRE Product Use Management: Cervicitis (including findings on exam)



***Consider syndromic management pending results of testing and per clinician discretion.**

Protocol Reference: Section 9.4

ASPIRE Product Use Management: Genital petechia(e), genital ecchymosis



Protocol Reference: Section 9.5

ASPIRE Product Use Management: Participant Non-compliance or other safety concerns

- HOLD product if a participant is unable or unwilling to comply with required study procedures, or otherwise might be put at undue risk to her safety and well-being by continuing product use, according to the judgment of the IoR/ designee.
- CONSULT the PSRT on all product holds instituted for this reason for further guidance on resuming product use, continuing the temporary hold, or progressing to permanent discontinuation.
- If the underlying reason for the product hold resolves, CONSULT the PSRT to resume study product at that time.

Protocol Reference: Section 9.3

ASPIRE Product Use Management: CO-ENROLLMENT

- If co-enrollment in another study is identified, obtain as much information as possible about the other study from the participant and the other study team.
- HOLD product upon identification of co-enrollment *unless* the other study is known to not involve a study product and/or confirmation is available from the other study team that the participant is not using another study product.
- CONSULT the PSRT on further management of the participant.
- Schedule the participant to return when a response from the PSRT is expected.

Protocol Reference: Section 9.3